Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wound Management buys ortho firm to exploit $10bn opportunity

This article was originally published in Clinica

Executive Summary

In a bid to broaden its platform technologies that target growing patient populations, Wound Management Technologies has purchased biomaterial expert Resorbable Orthopedics. The deal provides Wound Management with complementary orthopaedic biomaterials such as a resorbable bone wax used to stop blood flow and a delivery system for osteogenic and osteoinductive bone void fillers. According to Fort Worth, Texas-based Wound Management, the orthopaedic biomaterial market is worth around $10bn and is driven by improved patient benefits, shorter FDA approval cycles and an ageing population. The total market value for the biomaterial sector is approximately $28bn and is expected to exceed $58bn in the next five years. For an undisclosed fee, Resorbable Orthopaedics has become a wholly-owned subsidiary of Wound Management.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044420

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel